Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Shuai Wang, Fen‐Er Chen
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114334-114334
Closed Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Targeting p53 pathways: mechanisms, structures and advances in therapy
Haolan Wang, Ming Guo, Hudie Wei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 379
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 141
Spirooxindole: A Versatile Biologically Active Heterocyclic Scaffold
Siva S. Panda, Adel S. Girgis, Marian N. Aziz, et al.
Molecules (2023) Vol. 28, Iss. 2, pp. 618-618
Open Access | Times Cited: 64
Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours
Kamilla J. A. Bigos, Conrado Guerrero Quiles, Sapna Lunj, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 27
Small molecules targeting protein–protein interactions for cancer therapy
Defa Wu, Yang Li, Lang Zheng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4060-4088
Open Access | Times Cited: 32
Effects of Mdm2 Inhibitors on Cellular Viability of Breast Cancer Cell Lines HP100, MCF7
Hany Akeel Al-Hussaniy, Mohammed J. AL-Zobaidy
Bratislavské lekárske listy/Bratislava medical journal (2024) Vol. 125, Iss. 10, pp. 627-634
Open Access | Times Cited: 10
The hybrid lipoplex induces cytoskeletal rearrangement via autophagy/RhoA signaling pathway for enhanced anticancer gene therapy
Xueyi Hu, Yichun Wang, Ruohan Wang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
Jasmin Linh On, Sakineh Ghaderi, Carina Rittmann, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1078-1078
Open Access | Times Cited: 1
New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future
Lucio Dell’Atti, Nicoletta Bianchi, Gianluca Aguiari
Cancers (2022) Vol. 14, Iss. 15, pp. 3616-3616
Open Access | Times Cited: 36
Small-molecule correctors and stabilizers to target p53
Maryam M.J. Fallatah, Fiona V. Law, Warren Chow, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 5, pp. 274-289
Open Access | Times Cited: 20
Molecular Docking and Molecular Dynamics Studies Reveal the Anticancer Potential of Medicinal-Plant-Derived Lignans as MDM2-P53 Interaction Inhibitors
Tagyedeen H. Shoaib, Nihal Abdelmoniem, Rua M. Mukhtar, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6665-6665
Open Access | Times Cited: 18
Cytotoxic Effect of YH239-EE and Its Enantiomer on MCF7 Cell Line
Hany Akeel Al-Hussaniy, Mohammed AL-Zobaidy
Asian Pacific Journal of Cancer Prevention (2024) Vol. 25, Iss. 6, pp. 2133-2138
Open Access | Times Cited: 6
Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors
Margarida Espadinha, Elizabeth A. Lopes, Vanda Marques, et al.
European Journal of Medicinal Chemistry (2022) Vol. 241, pp. 114637-114637
Open Access | Times Cited: 24
Proteomic characterization of post-translational modifications in drug discovery
Linhui Zhai, Kai‐Feng Chen, Bingbing Hao, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 12, pp. 3112-3129
Open Access | Times Cited: 23
DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2–p53 Inhibitor
Anthony P. Silvestri, Qi Zhang, Yan Ping, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 6, pp. 820-826
Closed Access | Times Cited: 15
C3-Spirooxindoles: Divergent chemical synthesis and bioactivities (2018–2023)
Mohamed H. Helal, Medhat E. Owda, Amal T. Mogharbel, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107091-107091
Closed Access | Times Cited: 5
Insights into the Interaction Mechanisms of Peptide and Non-Peptide Inhibitors with MDM2 Using Gaussian-Accelerated Molecular Dynamics Simulations and Deep Learning
Wanchun Yang, Jian Wang, Lu Zhao, et al.
Molecules (2024) Vol. 29, Iss. 14, pp. 3377-3377
Open Access | Times Cited: 5
Substrate and Functional Diversity of Protein Lysine Post-translational Modifications
Bingbing Hao, Kaifeng Chen, Linhui Zhai, et al.
Genomics Proteomics & Bioinformatics (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities
A. Awan, Maryiam Jama Ali Osman, Omar M. Khan
Cells (2025) Vol. 14, Iss. 2, pp. 69-69
Open Access
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins
Ishaar P. Ganesan, Hiroaki Kiyokawa
Cancers (2025) Vol. 17, Iss. 4, pp. 626-626
Open Access
TDP‐43/ALKBH5‐mediated m6A modification of CDC25A mRNA promotes glioblastoma growth by facilitating G1/S cell cycle transition
Yunxiao Zhang, Sidi Xie, Weizhao Li, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Dependence on Mdm2 for Mdm4 inhibition of p53 activity
Shunbin Xiong, Yun Zhang, Xin Zhou, et al.
Cancer Letters (2025), pp. 217622-217622
Closed Access
FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1/3 and CK1α to activate p53 and inhibit NF-κB signaling
Daiki Kanaoka, Mitsuo Yamada, Hironori Yokoyama, et al.
Cancer Research Communications (2024)
Open Access | Times Cited: 3
Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer
Yan Li, Guangyu Li, Chenwei Zuo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116367-116367
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top